CD44 and cancer: Of particular interest in developmentally based pediatric cancers, oncogenic epigenetic changes are known to affect genes, such as SRY (sex-determining region Y)-box 2 (SOX2), CD44 molecule (CD44), and prominin-1 (CD133), contributing to enhanced capacity for self-renewal and stem-cell-like phenotypes [40,125,126,127].